Y-mAbs Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments

[ad_1] Q4 2022 DANYELZA® record net product revenues of $16.4 million, driving YoY growth of 71% and 31% sequential increase compared to Q3 2022 DANYELZA conditional marketing authorization granted in…

Y-mAbs to Announce 2022 Financial and Operating Results on March 30, 2023

[ad_1] Y-mAbs Therapeutics, Inc NEW YORK, March 21, 2023 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results…